Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2013-07-16 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation - Quarterly Briefing June 2013 25 pages 419.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Investor Briefing' and includes forward-looking statements, a CEO presentation date, and detailed business and strategic information. It focuses on quarterly events and progress updates, typical of a quarterly or interim report. The document length is substantial (15,000 characters), indicating it contains substantive financial and operational data rather than just an announcement or summary. There is no indication that this is a full annual report (10-K) or an earnings release (ER) which are usually shorter and more focused on financial highlights. It is not a call transcript or a regulatory filing. Therefore, the document best fits the category of an Interim / Quarterly Report (IR). Q4 2013
2013-07-16 English
Appendix 4C - quarterly 5 pages 105.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities admitted on the basis of commitments.' It contains detailed financial data including consolidated cash flow statements for the current quarter and year to date, payments to directors, non-cash financing and investing activities, financing facilities, and reconciliation of cash. The presence of detailed financial statements and analysis for a quarter ending 30 June 2013 indicates this is a comprehensive interim financial report. The document length is 15,000 characters, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2013
2013-07-16 English
PHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL 1 page
Call Transcript Classification · 90% confidence The document is a media release announcing a quarterly investor conference call scheduled for 18 July 2013. It mentions that an investor presentation will be lodged prior to the call and provides telephone and online access details for the call. The document does not contain any financial data or detailed financial analysis itself, nor does it include a transcript of the call. It is an announcement about the call event, not the call transcript or a financial report. Therefore, the document fits the category of a Call Transcript announcement, but since it is only announcing the call and not providing the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the conference call event. Confidence is high due to clear mention of the quarterly investor conference call and related details.
2013-07-15 English
Pharmaxis Awarded Two ARC Linkage Grants 2 pages 130.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 5 July 2013 from Pharmaxis Ltd announcing that two of its research projects have been awarded funding under the Australian Research Council (ARC) Linkage Projects scheme. The content focuses on research funding, project descriptions, and company background. There is no financial data, no mention of financial results, no regulatory filings, no management or board changes, no voting results, no legal proceedings, no capital or financing updates, and no earnings information. The document is a public announcement of a grant award and research funding, which does not fit into any of the specific financial or regulatory report categories. It is not a report itself but a press release about research funding. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2013-07-04 English
European CF Clinical Trial in Paediatric Patients Begins 2 pages 131.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 20 June 2013 from Pharmaxis Ltd announcing the start of a European clinical trial for a pharmaceutical product (Bronchitol) in pediatric cystic fibrosis patients. It describes the trial design, endpoints, and other clinical details. There is no financial data, regulatory filing, or report attached or referenced. The content is a public announcement about a clinical trial initiation, not a financial report, regulatory filing, or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a press/media release about clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing that does not fit other categories.
2013-06-19 English
Pharmaxis Presents New Analyses of Pooled CF Data at EU Meet 2 pages 128.6KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 18 June 2013 from Pharmaxis Ltd presenting new analyses of pooled cystic fibrosis data from phase 3 studies. It discusses clinical trial results, patient benefits, and healthcare system value, but does not contain actual financial statements or detailed financial performance data. It is a communication of clinical and product development progress rather than a financial report or regulatory filing. The document is not an earnings release, annual report, or interim report, nor does it announce changes in management, capital structure, or legal proceedings. It is a public relations/media release focused on clinical data presentation at a conference. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2013-06-17 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.